Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis

Eli Lilly and Company204 enrolled

Overview

The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

204

Conditions

Plaque Psoriasis

Interventions

Ixekizumab Auto-InjectorDRUG

Administered SC by auto-injector

Ixekizumab Prefilled SyringeDRUG

Administered SC by prefilled syringe

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Present with chronic plaque psoriasis based on a confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to randomization * At least 10% Body Surface Area (BSA) of Psoriasis at screening and at randomization * Static Physician Global Assessment (sPGA) score of at least 3 AND Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at randomization * Candidate for phototherapy and/or systemic therapy * Men must agree to use a reliable method of birth control during the study * Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment Exclusion Criteria: * Pustular, erythrodermic, and/or guttate forms of psoriasis * History of drug-induced psoriasis * Clinically significant flare of psoriasis during the 12 weeks prior to randomization * Concurrent or recent use of any biologic agent * Received systemic psoriasis therapy \[such as psoralen and ultraviolet A (PUVA) light therapy\] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization * Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study * Have participated in any study with interleukin-17 (IL-17) antagonists, including Ixekizumab * Serious disorder or illness other than plaque psoriasis * Serious infection within the last 3 months * Breastfeeding or nursing (lactating) women

Locations (25)

Outcomes

Primary Outcomes

Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) by Drug Delivery Device

Cmax by drug delivery device (prefilled syringe or auto-injector) of Ixekizumab, after the 160 mg starting dose was administered on Day 0.

Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)

PK: Area Under the Concentration Time Curve From Time Zero to Last Measured Concentration Value (AUC 0-[Tlast]) by Drug Delivery Device

AUC 0-tlast by drug delivery device (prefilled syringe or auto-injector) of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours.

Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)

Secondary Outcomes

PK: Cmax of Ixekizumab by Site of Injection (Arm, Thigh or Abdomen)

Cmax by site of injection of Ixekizumab, after the 160 mg starting dose was administered on Day 0.

Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)

PK: AUC 0-tlast by Site of Injection (Arm, Thigh or Abdomen)

AUC 0-tlast by site of injection of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours.

Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)

PK: Cmax by Body Weight

Cmax by body weight of Ixekizumab, after the 160 mg starting dose was administered on Day 0. Body weight is defined by (Low: \<80 kilogram (kg), Medium: 80-100 kg, or High: \>100 kg).

Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Anaheim, California, United States

Bakersfield, California, United States

Santa Monica, California, United States

Miami, Florida, United States

Ocala, Florida, United States

Atlanta, Georgia, United States

Newnan, Georgia, United States

Arlington Heights, Illinois, United States

Evansville, Indiana, United States

Louisville, Kentucky, United States

...and 15 more locations

PK: AUC 0-tlast by Body Weight

AUC 0-tlast by body weight of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours. Body weight is defined by (Low: \<80 kg, Medium: 80-100 kg, or High: \>100 kg).

Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)

Percentage of Participants Achieving a ≥75%, ≥ 90% and 100% Improvement in Psoriasis Area and Severity Index (PASI): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index (PASI)

PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 or no Ps to 72 for the most severe disease. Participants achieving PASI 75, 90, or 100 are defined as having an improvement of at least 75%, 90%, or of 100%, respectively, in the PASI scores compared to baseline.

Time frame: Week 12

Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment (sPGA)

The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.

Time frame: Week 12

Percentage of Participants With a Static Physician Global Assessment (sPGA) (0)

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).

Time frame: Week 12

Percentage of Device Operation Failures

Device operation failure (that is, incomplete dose administration) was defined as an event during the treatment period (week 0 to week 12) when the participant indicated that a complete dose of ixekizumab was not delivered and/or the drug delivery device did not perform as expected per the directions for use.

Time frame: Baseline through Week 12

Percentage of Participants With Anti-Ixekizumab Antibodies

The percentage of participants with treatment-emergent positive anti-ixekizumab antibodies at anytime post-baseline were summarized by drug delivery device group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

Time frame: Baseline to Week 12

SQAAQ Item Scores: Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)

The SQAAQ is a self-administered questionnaire which provides an assessment of ease of use and confidence with using a device to administer a subcutaneous injection of drug. Participants and injection assistants responded to questionnaire items using a 7-point Likert scale (from "Strongly Disagree" to "Strongly Agree"). 1 represents "Strongly Disagree" while 7 represents "Strongly Agree". The ease of use and confidence of ixekizumab subcutaneous administrations across drug delivery device groups were evaluated by SQAAQ item scores at each post baseline visit.

Time frame: Baseline, Week 4 and Week 8